{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:05:10Z","timestamp":1793135110858,"version":"4.5.0"},"reference-count":421,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["RCBS20221008093243060"],"award-info":[{"award-number":["RCBS20221008093243060"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jare.2025.06.009","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:36:09Z","timestamp":1749756969000},"page":"967-1003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics"],"prefix":"10.1016","volume":"81","author":[{"given":"Kiavash","family":"Hushmandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najma","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Einollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokooh","family":"Salimimoghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0005","doi-asserted-by":"crossref","DOI":"10.2196\/36244","article-title":"Exploring urological malignancies on pinterest: content analysis","volume":"8","author":"Herbert","year":"2022","journal-title":"JMIR Cancer"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0010","first-page":"64","article-title":"Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021","volume":"11","author":"Zi","year":"2024","journal-title":"Mil Med Res"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41391-023-00774-z","article-title":"Molecular mechanisms underpinning favourable physiological adaptations to exercise prehabilitation for urological cancer surgery","volume":"27","author":"Blackwell","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jare.2025.06.009_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1114203","article-title":"Identifying novel biomarkers associated with bladder cancer treatment outcomes","volume":"13","author":"Castaneda","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"48","key":"10.1016\/j.jare.2025.06.009_b0030","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1038\/sj.onc.1205802","article-title":"Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer","volume":"21","author":"Osada","year":"2002","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b0035","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1080\/15548627.2021.1985917","article-title":"The pro-autophagic protein AMBRA1 coordinates cell cycle progression by regulating CCND (cyclin D) stability","volume":"17","author":"Maiani","year":"2021","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b0040","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0050","doi-asserted-by":"crossref","first-page":"21645","DOI":"10.1038\/s41598-024-69252-3","article-title":"A retrospective analysis suggests PTEN expression is associated with favorable clinicopathological features of breast cancer","volume":"14","author":"Derkyi-Kwarteng","year":"2024","journal-title":"Sci Rep"},{"issue":"6441","key":"10.1016\/j.jare.2025.06.009_b0055","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau0159","article-title":"Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway","volume":"364","author":"Lee","year":"2019","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0060","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031500","article-title":"Ras-specific GTPase-activating proteins-structures, mechanisms, and interactions","volume":"9","author":"Scheffzek","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jare.2025.06.009_b0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b0070","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/2159-8290.CD-20-1351","article-title":"Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling","volume":"11","author":"Adamopoulos","year":"2021","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0075","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b0080","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors' current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-022-00273-9","article-title":"Harnessing the immunotherapeutic potential of CDK4\/6 inhibitors in melanoma: is timing everything?","volume":"6","author":"Lelliott","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0090","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1038\/s41467-021-25422-9","article-title":"Co-targeting CDK4\/6 and AKT with endocrine therapy prevents progression in CDK4\/6 inhibitor and endocrine therapy-resistant breast cancer","volume":"12","author":"Alves","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/genes5010147","article-title":"Molecular mechanisms of DNA replication checkpoint activation","volume":"5","author":"Recolin","year":"2014","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jare.2025.06.009_b0100","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"issue":"45","key":"10.1016\/j.jare.2025.06.009_b0105","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1038\/sj.onc.1204813","article-title":"Role of RAD51 in sister-chromatid exchanges in mammalian cells","volume":"20","author":"Lambert","year":"2001","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.jare.2025.06.009_b0110","doi-asserted-by":"crossref","first-page":"8129","DOI":"10.1093\/nar\/gkx565","article-title":"The role of poly ADP-ribosylation in the first wave of DNA damage response","volume":"45","author":"Liu","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007716","article-title":"Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer","volume":"12","author":"Martincuks","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0120","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b0125","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/biom9040153","article-title":"The PTEN(-)PI3K axis in cancer","volume":"9","author":"Papa","year":"2019","journal-title":"Biomolecules"},{"issue":"6382","key":"10.1016\/j.jare.2025.06.009_b0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/358157a0","article-title":"Platelet-derived growth factor stimulates synthesis of Ptdlns (3, 4, 5) P3 by activating a Ptdlns (4, 5) P2 3-OH kinase","volume":"358","author":"Hawkins","year":"1992","journal-title":"Nature"},{"issue":"6321","key":"10.1016\/j.jare.2025.06.009_b0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/351033a0","article-title":"Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils","volume":"351","author":"Stephens","year":"1991","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0150","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","article-title":"A pan-cancer proteogenomic atlas of PI3K\/AKT\/mTOR pathway alterations","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0155","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1073\/pnas.0408864102","article-title":"Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic","volume":"102","author":"Kang","year":"2005","journal-title":"PNAS"},{"issue":"23","key":"10.1016\/j.jare.2025.06.009_b0160","doi-asserted-by":"crossref","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Isakoff","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Di Leo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0170","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/annonc\/mdw320","volume":"27","author":"Vuylsteke","year":"2016","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.jare.2025.06.009_b0175","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-16-1764","article-title":"Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors","volume":"23","author":"Abramson","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b0180","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-020-00746-8","article-title":"PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma","volume":"21","author":"Sapon-Cousineau","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b0190","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0195","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1128\/MCB.26.6.2262-2272.2006","article-title":"Regulation and role of Raf-1\/B-Raf heterodimerization","volume":"26","author":"Rushworth","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"7781","key":"10.1016\/j.jare.2025.06.009_b0200","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2025.06.009_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"issue":"5545","key":"10.1016\/j.jare.2025.06.009_b0215","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1126\/science.1062023","article-title":"The guanine nucleotide-binding switch in three dimensions","volume":"294","author":"Vetter","year":"2001","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.jare.2025.06.009_b0220","doi-asserted-by":"crossref","first-page":"R563","DOI":"10.1016\/j.cub.2005.07.010","article-title":"Signaling interplay in Ras superfamily function","volume":"15","author":"Mitin","year":"2005","journal-title":"Curr Biol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0225","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0230","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033746","article-title":"Ras-mediated activation of the Raf family kinases","volume":"9","author":"Terrell","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b0235","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.cell.2015.04.045","article-title":"Alike but different: RAF paralogs and their signaling outputs","volume":"161","author":"Desideri","year":"2015","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b0240","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b0245","first-page":"3595","article-title":"Active Ras induces heterodimerization of cRaf and BRaf","volume":"61","author":"Weber","year":"2001","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.jare.2025.06.009_b0250","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0255","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0260","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"5\u20136","key":"10.1016\/j.jare.2025.06.009_b0265","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/10428199609054859","article-title":"Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma","volume":"23","author":"Siebert","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0270","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To cycle or not to cycle: a critical decision in cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0275","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0092-8674(93)90636-5","article-title":"Mammalian G1 cyclins","volume":"73","author":"Sherr","year":"1993","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b0280","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","article-title":"A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells","volume":"20","author":"Anders","year":"2011","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.jare.2025.06.009_b0285","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jare.2025.06.009_b0290","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1158\/1078-0432.CCR-13-1675","article-title":"Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma","volume":"19","author":"Rader","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.jare.2025.06.009_b0295","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/1078-0432.CCR-17-1819","article-title":"Mechanism of action and clinical impact of ribociclib-response","volume":"23","author":"Tripathy","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.06.009_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-016-0721-5","article-title":"Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"17","key":"10.1016\/j.jare.2025.06.009_b0305","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2\u2212 metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2025.06.009_b0310","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"10.1016\/j.jare.2025.06.009_b0315","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","article-title":"Genetic aberrations in the CDK4 Pathway are associated with innate resistance to PD-1 blockade in chinese patients with non-cutaneous melanoma","volume":"25","author":"Yu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7668","key":"10.1016\/j.jare.2025.06.009_b0320","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.jare.2025.06.009_b0325","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1038\/s41388-020-1284-6","article-title":"Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities","volume":"39","author":"Pancholi","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0330","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b0335","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0340","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-19-0751","article-title":"Biomarker analyses of response to cyclin-dependent kinase 4\/6 inhibition and endocrine therapy in women with treatment-naive metastatic breast cancer","volume":"26","author":"Finn","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0345","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1158\/1535-7163.MCT-18-0755","article-title":"Direct CDKN2 modulation of CDK4 alters target engagement of CDK4 inhibitor drugs","volume":"18","author":"Green","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"10.1016\/j.jare.2025.06.009_b0350","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-18-0410","article-title":"MAPK reliance via acquired CDK4\/6 inhibitor resistance in cancer","volume":"24","author":"de Leeuw","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0355","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3Kalpha inhibitors in breast cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0360","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clbc.2017.12.010","article-title":"BRCA2 reversion mutation associated with acquired resistance to olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy","volume":"18","author":"Gornstein","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0365","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2016.71.3677","article-title":"Somatic BRCA1\/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition","volume":"35","author":"Lheureux","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0370","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/1535-7163.MCT-17-0256","article-title":"Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations","volume":"19","author":"Park","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b0375","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0380","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","article-title":"Brca1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0385","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"issue":"7676","key":"10.1016\/j.jare.2025.06.009_b0390","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature24060","article-title":"BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing","volume":"550","author":"Zhao","year":"2017","journal-title":"Nature"},{"issue":"Pt 15","key":"10.1016\/j.jare.2025.06.009_b0395","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1242\/jcs.105353","article-title":"BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair","volume":"125","author":"Chapman","year":"2012","journal-title":"J Cell Sci"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b0400","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.jare.2025.06.009_b0405","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4939-6993-7_9","article-title":"Identification of protein substrates of specific PARP enzymes using analog-sensitive PARP mutants and a \u201cClickable\u201d NAD(+) analog","volume":"1608","author":"Gibson","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b0410","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"21","key":"10.1016\/j.jare.2025.06.009_b0415","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"issue":"6330","key":"10.1016\/j.jare.2025.06.009_b0420","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b0425","first-page":"891","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"383","author":"de Bono","year":"2020","journal-title":"Reply. N Engl J Med."},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b0430","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.apsb.2020.01.003","article-title":"Small-molecule MDM2\/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives","volume":"10","author":"Fang","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"14","key":"10.1016\/j.jare.2025.06.009_b0435","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes Dev"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b0440","first-page":"582","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53-or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood, J Am Soc Hematol"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b0445","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/emboj\/cdg114","article-title":"BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination","volume":"22","author":"Sengupta","year":"2003","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b0450","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.160225","article-title":"A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining","volume":"6","author":"Moureau","year":"2016","journal-title":"Open Biol"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b0455","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3390\/cancers11081178","article-title":"p21 in cancer research","volume":"11","author":"Shamloo","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0460","first-page":"1999","article-title":"Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells","volume":"39","author":"Janyst","year":"2018","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0465","doi-asserted-by":"crossref","first-page":"512","DOI":"10.18632\/oncotarget.23070","article-title":"HDAC inhibitor PAC-320 induces G2\/M cell cycle arrest and apoptosis in human prostate cancer","volume":"9","author":"Dong","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b0470","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/onc.2012.84","article-title":"Synthetic lethality of Chk1 inhibition combined with p53 and\/or p21 loss during a DNA damage response in normal and tumor cells","volume":"32","author":"Origanti","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0475","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3892\/or.2014.3538","article-title":"Association of p53\/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients","volume":"32","author":"Xie","year":"2014","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0480","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3904\/kjim.2003.18.2.98","article-title":"Prognostic significance of p21 and p53 expression in gastric cancer","volume":"18","author":"Seo","year":"2003","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0485","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3892\/ol.2013.1381","article-title":"Prognostic significance of p21, p27 and survivin protein expression in patients with oral squamous cell carcinoma","volume":"6","author":"Zhang","year":"2013","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b0490","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ncb3378","article-title":"Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing","volume":"18","author":"Galanos","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0495","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13059-018-1401-9","article-title":"Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability","volume":"19","author":"Galanos","year":"2018","journal-title":"Genome Biol"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0500","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jmb.2017.03.030","article-title":"Mutant p53 in cancer: accumulation, gain-of-function, and therapy","volume":"429","author":"Yue","year":"2017","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0505","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/0008-5472.CAN-19-1036","article-title":"Gain-of-function mutant p53 R273H interacts with replicating DNA and PARP1 in breast cancer","volume":"80","author":"Xiao","year":"2020","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.jare.2025.06.009_b0510","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"10.1016\/j.jare.2025.06.009_b0515","doi-asserted-by":"crossref","first-page":"S385","DOI":"10.21037\/atm.2019.12.130","article-title":"Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma","volume":"7","author":"Shaya","year":"2019","journal-title":"Ann Transl Med."},{"issue":"21","key":"10.1016\/j.jare.2025.06.009_b0520","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2217\/fon-2022-0433","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial","volume":"18","author":"Smith","year":"2022","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0525","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13167-022-00288-z","article-title":"Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine - comprehensive effects of phytochemicals in primary, secondary and tertiary care","volume":"13","author":"Mazurakova","year":"2022","journal-title":"EPMA J"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13167-022-00276-3","article-title":"Prostate cancer treatment costs increase more rapidly than for any other cancer\u2014how to reverse the trend?","volume":"13","author":"Ellinger","year":"2022","journal-title":"EPMA J"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0535","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s13167-020-00214-1","article-title":"Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions","volume":"11","author":"Kucera","year":"2020","journal-title":"EPMA J"},{"key":"10.1016\/j.jare.2025.06.009_b0540","article-title":"Innovative smart biosensors for cancer theranostics: a new frontier in detection, diagnosis, and beyond","volume":"43","author":"Dhasmana","year":"2025","journal-title":"Cancer Treat Res Commun."},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0545","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0550","doi-asserted-by":"crossref","DOI":"10.58647\/DRUGREPO.24.2.0016","article-title":"Unlocking drug repurposing clinical trials: resources for investigators","volume":"1","author":"Peterson","year":"2024","journal-title":"Drug Repurposing."},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0555","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13167-024-00358-4","article-title":"Mini-encyclopedia of mitochondria-relevant nutraceuticals protecting health in primary and secondary care-clinically relevant 3PM innovation","volume":"15","author":"Golubnitschaja","year":"2024","journal-title":"EPMA J"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b0560","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1758834017719215","article-title":"Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications","volume":"9","author":"Terada","year":"2017","journal-title":"Ther Adv Med Oncol."},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0565","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10147-017-1122-1","article-title":"Biomarkers to predict prognosis and response to checkpoint inhibitors","volume":"22","author":"Yuasa","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0570","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10147-018-1260-0","article-title":"Recent advances in medical therapy for metastatic urothelial cancer","volume":"23","author":"Yuasa","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0580","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b0585","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b0590","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10236","key":"10.1016\/j.jare.2025.06.009_b0595","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0600","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-5347(17)48996-8","article-title":"Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium","volume":"133","author":"Sternberg","year":"1985","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0605","first-page":"507","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0610","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b0615","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jare.2025.06.009_b0625","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0630","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b0635","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.06.009_b0640","doi-asserted-by":"crossref","first-page":"v328","DOI":"10.1093\/annonc\/mdz248.004","article-title":"Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from> 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study","volume":"30","author":"De Bono","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0645","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","article-title":"Prostate cancer and PARP inhibitors: progress and challenges","volume":"14","author":"Teyssonneau","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b0650","article-title":"Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study","author":"Chi","year":"2021","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.jare.2025.06.009_b0655","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2025.06.009_b0660","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3332\/ecancer.2019.905","article-title":"The use of intravesical BCG in urothelial carcinoma of the bladder","volume":"13","author":"Alhunaidi","year":"2019","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0665","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.euf.2018.07.005","article-title":"Combination intravesical chemotherapy for non-muscle-invasive bladder cancer","volume":"4","author":"Steinberg","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b0670","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.185.7.1327","article-title":"CTLA-4\u2013B7 interaction is sufficient to costimulate T cell clonal expansion","volume":"185","author":"Wu","year":"1997","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0675","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2004.06.017","article-title":"B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse","volume":"21","author":"Pentcheva-Hoang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.jare.2025.06.009_b0680","article-title":"Novel combination therapies for the treatment of bladder cancer","volume":"10","author":"Peng","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0685","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41419-024-06837-w","article-title":"The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies","volume":"15","author":"Yu","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0690","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b0695","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/1078-0432.CCR-22-3882","article-title":"Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance","volume":"29","author":"Aggen","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0700","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41419-024-06665-y","article-title":"A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jare.2025.06.009_b0705","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1151701","article-title":"Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis","volume":"13","author":"Rouvinov","year":"2023","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.jare.2025.06.009_b0710","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0715","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0720","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12967-021-02865-8","article-title":"Metabolic classification of bladder cancer based on multi-omics integrated analysis to predict patient prognosis and treatment response","volume":"19","author":"Tang","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2025.06.009_b0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-13-120","article-title":"The mitochondrial C16069T polymorphism, not mitochondrial D310 (D-loop) mononucleotide sequence variations, is associated with bladder cancer","volume":"13","author":"Shakhssalim","year":"2013","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0730","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/beta-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b0735","article-title":"Emerging roles of aldehyde dehydrogenase isoforms in anti-cancer therapy resistance","volume":"9","author":"Zanoni","year":"2022","journal-title":"Front Med (Lausanne)."},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0740","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/biomedicines9040392","article-title":"Changing the History of Prostate Cancer with New Targeted Therapies","volume":"9","author":"Hernando Polo","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0745","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ucl.2016.01.001","article-title":"Physiology of the hypothalamic pituitary gonadal axis in the male","volume":"43","author":"Corradi","year":"2016","journal-title":"Urol Clin North Am"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b0750","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nrendo.2016.70","article-title":"Control of puberty onset and fertility by gonadotropin-releasing hormone neurons","volume":"12","author":"Herbison","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"27","key":"10.1016\/j.jare.2025.06.009_b0755","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2011.35.2005","article-title":"Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically","volume":"29","author":"Ryan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jare.2025.06.009_b0760","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1080\/14656566.2021.1948012","article-title":"Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer","volume":"22","author":"Moussa","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0765","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5534\/wjmh.180040","article-title":"Role of androgen receptor in prostate cancer: a review","volume":"37","author":"Fujita","year":"2019","journal-title":"World J Mens Health."},{"issue":"49","key":"10.1016\/j.jare.2025.06.009_b0770","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0775","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nrclinonc.2013.14","article-title":"Prostate cancer: the androgen receptor remains front and centre","volume":"10","author":"Saylor","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0780","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/ncponc0765","article-title":"Drug insight: role of the androgen receptor in the development and progression of prostate cancer","volume":"4","author":"Taplin","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0785","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b0790","doi-asserted-by":"crossref","first-page":"15651","DOI":"10.18632\/oncotarget.14926","article-title":"Detection fidelity of AR mutations in plasma derived cell-free DNA","volume":"8","author":"Goldstein","year":"2017","journal-title":"Oncotarget"},{"issue":"312","key":"10.1016\/j.jare.2025.06.009_b0795","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b0800","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14656566.2017.1329820","article-title":"Darolutamide (ODM-201) for the treatment of prostate cancer","volume":"18","author":"Shore","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0805","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0810","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0815","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acs.biochem.9b00848","article-title":"PROTACs as potential therapeutic agents for cancer drug resistance","volume":"59","author":"Sun","year":"2019","journal-title":"Biochemistry"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b0820","first-page":"435","article-title":"Targeted degraders clear first safety hurdles","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0825","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0830","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00345-019-02937-x","article-title":"Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study","volume":"38","author":"Sawazaki","year":"2020","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0835","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.eururo.2014.05.037","article-title":"Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer","volume":"66","author":"Boccon-Gibod","year":"2014","journal-title":"Eur Urol"},{"issue":"23","key":"10.1016\/j.jare.2025.06.009_b0840","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b0845","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0850","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10741-020-09984-2","article-title":"Hormonal prostate cancer therapies and cardiovascular disease: a systematic review","volume":"27","author":"Cereda","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"1\u20132","key":"10.1016\/j.jare.2025.06.009_b0855","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","article-title":"CYP17 inhibitors for prostate cancer therapy","volume":"125","author":"Vasaitis","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0860","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0865","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b0870","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0875","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1078-0432.CCR-15-1432","article-title":"Androgen receptor modulation optimized for response (ARMOR) Phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer","volume":"22","author":"Montgomery","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0880","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2019.08.034","article-title":"Androgen receptor modulation optimized for response-splice variant: a phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer","volume":"76","author":"Taplin","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0885","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0890","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/cancers12061367","article-title":"PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2025.06.009_b0895","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fonc.2018.00653","article-title":"New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen","volume":"8","author":"Cimadamore","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b0900","series-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy. Seminars in nuclear medicine","author":"Wester","year":"2019"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0905","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874471012666190729151540","article-title":"Toward the discovery and development of PSMA targeted inhibitors for nuclear medicine applications","volume":"13","author":"Pastorino","year":"2020","journal-title":"Curr Radiopharm"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0910","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/jon.12856","article-title":"PET\/CT using 68Ga\u2010PSMA\u2010617 versus 18F\u2010fluorodeoxyglucose to differentiate low\u2010and high\u2010grade gliomas","volume":"31","author":"Liu","year":"2021","journal-title":"J Neuroimaging"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b0915","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"10.1016\/j.jare.2025.06.009_b0920","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1021\/acs.analchem.0c01187","article-title":"Multifaceted bioanalytical methods for the comprehensive pharmacokinetic and catabolic assessment of MEDI3726, an anti-prostate-specific membrane antigen pyrrolobenzodiazepine antibody-drug conjugate","volume":"92","author":"Huang","year":"2020","journal-title":"Anal Chem"},{"issue":"13","key":"10.1016\/j.jare.2025.06.009_b0925","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-20-4528","article-title":"Phase I study of MEDI3726: A prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mcrpc after failure of abiraterone or enzalutamide","volume":"27","author":"de Bono","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b0930","article-title":"Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"12","author":"Sun","year":"2020","journal-title":"Cureus"},{"issue":"10276","key":"10.1016\/j.jare.2025.06.009_b0935","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0940","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pros.23922","article-title":"PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study","volume":"80","author":"Petrylak","year":"2020","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0945","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pros.22749","article-title":"Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy","volume":"74","author":"Ma","year":"2014","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0950","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0955","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"issue":"5\u20136","key":"10.1016\/j.jare.2025.06.009_b0960","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0965","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.trecan.2020.05.011","article-title":"DNA damage repair deficiency in prostate cancer","volume":"6","author":"Burdak-Rothkamm","year":"2020","journal-title":"Trends Cancer."},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0970","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b0975","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b0980","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.jare.2025.06.009_b0985","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b0990","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-18-0856","article-title":"Immune activation in mismatch repair\u2013deficient carcinogenesis: more than just mutational rate","volume":"26","author":"Willis","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b0995","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1000","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer Neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1010","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1172\/JCI125184","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rodrigues","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41585-018-0121-y","article-title":"Immunotherapy for lethal prostate cancer","volume":"16","author":"Rescigno","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-018-0342-x","article-title":"Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b1025","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrm.2016.27","article-title":"Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases","volume":"17","author":"Hydbring","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.tcb.2016.08.009","article-title":"Fueling the cell division cycle","volume":"27","author":"Salazar-Roa","year":"2017","journal-title":"Trends Cell Biol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1045","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","article-title":"A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer","volume":"27","author":"Palmbos","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"issue":"7686","key":"10.1016\/j.jare.2025.06.009_b1055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"6320","key":"10.1016\/j.jare.2025.06.009_b1065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","article-title":"Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2025.06.009_b1075","series-title":"Targeting p53 for the treatment of cancer. Seminars in cancer biology","author":"Duffy","year":"2022"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1080","doi-asserted-by":"crossref","DOI":"10.1172\/JCI123791","article-title":"Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers","volume":"129","author":"Malekzadeh","year":"2021","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1090","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clgc.2019.03.005","article-title":"A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer: canadian cancer trials group study IND205","volume":"17","author":"Hotte","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"AKT as a therapeutic target for cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1115","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/beta-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jare.2025.06.009_b1120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-3-030-32656-2_16","article-title":"Wnt\/beta-catenin signaling and prostate cancer therapy resistance","volume":"1210","author":"Yeh","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b1125","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-17-3006","article-title":"Inhibition of the Wnt\/beta-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b1130","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/cas.13636","article-title":"alpha-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-025-02306-w","article-title":"Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation","volume":"24","author":"Tufail","year":"2025","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1140","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","article-title":"Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity","volume":"51","author":"Katoh","year":"2017","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1145","article-title":"The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton","volume":"2013","author":"Roberts","year":"2013","journal-title":"Prostate Cancer."},{"issue":"13","key":"10.1016\/j.jare.2025.06.009_b1150","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b1155","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4161\/cbt.9.8.11112","article-title":"Bone-specific growth inhibition of prostate cancer metastasis by atrasentan","volume":"9","author":"Drake","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jare.2025.06.009_b1160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-2-16","article-title":"Endothelin receptors as novel targets in tumor therapy","volume":"2","author":"Bagnato","year":"2004","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1165","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju013","article-title":"Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421","volume":"106","author":"Lara","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1170","first-page":"318","article-title":"Alterations in TGFbeta signaling during prostate cancer progression","volume":"9","author":"Thompson-Elliott","year":"2021","journal-title":"Am J Clin Exp Urol."},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1175","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ccell.2015.04.009","article-title":"The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer metastases to bone","volume":"27","author":"Fournier","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2025.06.009_b1180","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1185","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGF\u03b2 Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"Knudson","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jare.2025.06.009_b1190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cytogfr.2019.10.004","article-title":"The transition model of RTK activation: a quantitative framework for understanding RTK signaling and RTK modulator activity","volume":"49","author":"Paul","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1195","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1200","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jare.2025.06.009_b1205","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2014.00222","article-title":"SRC: marker or actor in prostate cancer aggressiveness","volume":"4","author":"Vlaeminck-Guillem","year":"2014","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clgc.2020.05.013","article-title":"A phase 2 trial of abiraterone followed by randomization to addition of dasatinib or sunitinib in men with metastatic castration-resistant prostate cancer","volume":"19","author":"Spetsieris","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1215","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pros.23119","article-title":"Saracatinib as a metastasis inhibitor in metastatic castration\u2010resistant prostate cancer: a University of Chicago Phase 2 Consortium and DOD\/PCF prostate cancer clinical trials consortium study","volume":"76","author":"Posadas","year":"2016","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1220","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clgc.2019.02.010","article-title":"Randomized phase II trial of abiraterone alone or with Dasatinib in men with metastatic castration-resistant prostate cancer (mCRPC)","volume":"17","author":"Dorff","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1225","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4143\/crt.2017.438","article-title":"Phase II study of Dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05)","volume":"50","author":"Choi","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1230","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.3332","article-title":"Assessment of adverse events from the patient perspective in a phase 3 metastatic castration-resistant prostate cancer clinical trial","volume":"6","author":"Dueck","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1235","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.11.006","article-title":"Cabozantinib for progressive metastatic castration-resistant prostate cancer following docetaxel: combined analysis of two phase 3 trials","volume":"3","author":"Sonpavde","year":"2020","journal-title":"Eur Urol Oncol."},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b1240","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","article-title":"Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells","volume":"72","author":"Mulholland","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b1250","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/bjc.2011.163","article-title":"Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer","volume":"104","author":"Mukherjee","year":"2011","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.jare.2025.06.009_b1255","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-20-2306","article-title":"Dual blockade of c-MET and the androgen receptor in metastatic castration-resistant prostate cancer: a phase i study of concurrent enzalutamide and crizotinib","volume":"26","author":"Tripathi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1260","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/1078-0432.CCR-19-2389","article-title":"A phase II study of cabozantinib and androgen ablation in patients with hormone-naive metastatic prostate cancer","volume":"26","author":"Corn","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1265","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10637-018-0630-9","article-title":"Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)","volume":"36","author":"Monk","year":"2018","journal-title":"Invest New Drugs"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b1270","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-08-4554","article-title":"Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte","volume":"69","author":"Sonne","year":"2009","journal-title":"Cancer Res"},{"issue":"9512","key":"10.1016\/j.jare.2025.06.009_b1275","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(06)68305-0","article-title":"Testicular germ-cell cancer","volume":"367","author":"Horwich","year":"2006","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b1280","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.072067999","article-title":"Curing metastatic testicular cancer","volume":"99","author":"Einhorn","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.jare.2025.06.009_b1285","series-title":"Current chemotherapeutic approaches for recurrent or refractory germ cell tumors. Urologic Oncology: Seminars and Original Investigations","author":"Grimison","year":"2015"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b1290","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2016.1195808","article-title":"Investigational targeted therapies for the treatment of testicular germ cell tumors","volume":"25","author":"Oing","year":"2016","journal-title":"Expert Opin Invest Drugs"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1295","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.4161\/cc.7.11.5929","article-title":"Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation","volume":"7","author":"Xia","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jare.2025.06.009_b1300","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2013.13","article-title":"Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer","volume":"15","author":"Koster","year":"2013","journal-title":"Expert Rev Mol Med"},{"issue":"2\u20134","key":"10.1016\/j.jare.2025.06.009_b1305","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1387\/ijdb.130135mb","article-title":"Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors","volume":"57","author":"Cavallo","year":"2013","journal-title":"Int J Dev Biol"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b1310","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4161\/cc.9.7.11255","article-title":"p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors","volume":"9","author":"Li","year":"2010","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b1325","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/jclinpath-2012-201088","article-title":"PARP expression in germ cell tumours","volume":"66","author":"Mego","year":"2013","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1330","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10637-009-9280-2","article-title":"Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors","volume":"28","author":"Feldman","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jare.2025.06.009_b1335","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.4_suppl.367","article-title":"Sorafenib monotherapy in patients with inoperable\/recurrent germ cell tumors (GCT) refractory to chemotherapy: Phase II study","author":"Skoneczna","year":"2014","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1340","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/1078-0432.CCR-13-1131","article-title":"The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors","volume":"20","author":"Juliachs","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1345","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/bjc.2012.481","article-title":"Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer","volume":"107","author":"Nitzsche","year":"2012","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b1350","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-08-2170","article-title":"Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors","volume":"15","author":"Castillo-Avila","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1355","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CAD.0000000000000305","article-title":"Activity of nintedanib in germ cell tumors","volume":"27","author":"Steinemann","year":"2016","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1360","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canlet.2007.10.001","article-title":"Mutations of c-kit gene in bilateral testicular germ cell tumours in Japan","volume":"259","author":"Sakuma","year":"2008","journal-title":"Cancer Lett"},{"issue":"3B","key":"10.1016\/j.jare.2025.06.009_b1365","first-page":"1685","article-title":"Kit expression in male germ cell tumors","volume":"27","author":"Nikolaou","year":"2007","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1370","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b1375","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/annonc\/mdv310","article-title":"Bevacizumab\/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors","volume":"26","author":"Nieto","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1380","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/andr.299","article-title":"Cisplatin resistance in germ cell tumours: models and mechanisms","volume":"3","author":"Jacobsen","year":"2015","journal-title":"Andrology."},{"issue":"14","key":"10.1016\/j.jare.2025.06.009_b1385","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1158\/1078-0432.CCR-13-2868","article-title":"Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors","volume":"20","author":"Feldman","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1390","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1395","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10555-014-9533-1","article-title":"Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art","volume":"33","author":"Randall","year":"2014","journal-title":"Cancer Metastasis Rev"},{"issue":"18","key":"10.1016\/j.jare.2025.06.009_b1400","doi-asserted-by":"crossref","first-page":"9795","DOI":"10.3390\/ijms22189795","article-title":"Loss of Von Hippel-Lindau (VHL) tumor suppressor gene function: VHL-HIF pathway and advances in treatments for metastatic renal cell carcinoma (RCC)","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1405","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2021.11946","article-title":"Functions of circular RNAs in bladder, prostate and renal cell cancer (Review)","volume":"23","author":"Yang","year":"2021","journal-title":"Mol Med Rep"},{"issue":"23","key":"10.1016\/j.jare.2025.06.009_b1415","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.3390\/cancers14235733","article-title":"The underestimated role of the p53 pathway in renal cancer","volume":"14","author":"Amendolare","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b1420","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/cells8121619","article-title":"TGF-beta and microRNA interplay in genitourinary cancers","volume":"8","author":"Boguslawska","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1425","article-title":"Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: a multicohort study","volume":"4","author":"Qu","year":"2023","journal-title":"MedComm (2020)"},{"issue":"15","key":"10.1016\/j.jare.2025.06.009_b1430","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","article-title":"Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors","volume":"14","author":"Nickerson","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b1435","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/ki.2009.296","article-title":"The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy","volume":"76","author":"Clark","year":"2009","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1440","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1445","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1450","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b1455","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1460","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1465","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"issue":"15","key":"10.1016\/j.jare.2025.06.009_b1470","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b1475","article-title":"Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma","volume":"3","author":"Hagege","year":"2022","journal-title":"Cell Rep Med"},{"issue":"10189","key":"10.1016\/j.jare.2025.06.009_b1480","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.jare.2025.06.009_b1485","article-title":"Personalizing first-line management of metastatic renal cell carcinoma: leveraging current and novel therapeutic options","volume":"20","author":"Fitzgerald","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1490","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1495","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12962-023-00420-4","article-title":"Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"21","author":"Goudarzi","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1500","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.4143\/crt.2018.671","article-title":"Temsirolimus in asian metastatic\/recurrent non-clear cell renal carcinoma","volume":"51","author":"Lee","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1505","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/medsci4040016","article-title":"Combination of mTOR and MAPK inhibitors-a potential way to treat renal cell carcinoma","volume":"4","author":"Chauhan","year":"2016","journal-title":"Med Sci (Basel)"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1510","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.canlet.2014.11.012","article-title":"Pre-clinical evaluation of AZD-2014, a novel mTORC1\/2 dual inhibitor, against renal cell carcinoma","volume":"357","author":"Zheng","year":"2015","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b1515","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41589-021-00813-7","article-title":"Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth","volume":"17","author":"Lee","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jare.2025.06.009_b1520","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.673213","article-title":"Efficacy of a novel Bi-steric mTORC1 inhibitor in models of B-cell acute lymphoblastic leukemia","volume":"11","author":"Lee","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b1525","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.cell.2016.11.034","article-title":"CDK substrate phosphorylation and ordering the cell cycle","volume":"167","author":"Swaffer","year":"2016","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1530","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1535","article-title":"Inhibition of the CDK4\/6-cyclin D-Rb pathway by ribociclib augments chemotherapy and immunotherapy in renal cell carcinoma","volume":"2020","author":"Chen","year":"2020","journal-title":"Biomed Res Int"},{"issue":"601","key":"10.1016\/j.jare.2025.06.009_b1540","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay0482","article-title":"HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species","volume":"12","author":"Nicholson","year":"2019","journal-title":"Sci Signal"},{"issue":"36","key":"10.1016\/j.jare.2025.06.009_b1545","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.2549","article-title":"Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma","volume":"36","author":"Hsieh","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b1550","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2-VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b1555","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jare.2025.06.009_b1560","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von hippel-lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1565","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1570","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/s41467-020-18731-y","article-title":"HIF-2\u03b1 is indispensable for regulatory T cell function","volume":"11","author":"Hsu","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1575","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00262-019-02314-y","article-title":"Tumor infiltrating mast cells determine oncogenic HIF-2alpha-conferred immune evasion in clear cell renal cell carcinoma","volume":"68","author":"Xiong","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1580","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.eururo.2015.11.029","article-title":"Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel\u2013Lindau gene mutation status","volume":"70","author":"Messai","year":"2016","journal-title":"Eur Urol"},{"issue":"Suppl 14","key":"10.1016\/j.jare.2025.06.009_b1585","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1158\/1538-7445.AM2016-4022","article-title":"PT2385, a novel HIF-2\u03b1 antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration","volume":"76","author":"Han","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2025.06.009_b1590","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1071030","article-title":"Targeting c-Met in the treatment of urologic neoplasms: current status and challenges","volume":"13","author":"Su","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b1595","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/TCRM.S251673","article-title":"An evaluation of cabozantinib for the treatment of renal cell carcinoma: focus on patient selection and perspectives","volume":"18","author":"Iaxx","year":"2022","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1600","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1016\/j.clgc.2018.03.014","article-title":"Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an italian managed access program","volume":"16","author":"Procopio","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1605","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.clgc.2017.01.021","article-title":"Correlation of c-met expression and outcome in patients with renal cell carcinoma treated with sunitinib","volume":"15","author":"Peltola","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1610","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/his.13429","article-title":"Members of the IPTP. The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expert-driven recommendations","volume":"72","author":"Cubilla","year":"2018","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1615","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bju.12993","article-title":"Steering Committee of the Swedish National Penile Cancer R. Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival","volume":"117","author":"Kirrander","year":"2016","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1620","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00428-020-02831-7","article-title":"Prevalence of human papillomavirus and implication on survival in Chinese penile cancer","volume":"477","author":"Chu","year":"2020","journal-title":"Virchows Arch"},{"issue":"2 Suppl 1","key":"10.1016\/j.jare.2025.06.009_b1625","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.urology.2010.03.002","article-title":"Diagnosis and staging of penile cancer","volume":"76","author":"Heyns","year":"2010","journal-title":"Urology"},{"issue":"6b","key":"10.1016\/j.jare.2025.06.009_b1630","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/02841868809094366","article-title":"Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis","volume":"27","author":"Pizzocaro","year":"1988","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1635","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clgc.2015.07.009","article-title":"A Combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings","volume":"14","author":"Nicolai","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1640","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0974-7796.102659","article-title":"Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer","volume":"4","author":"Noronha","year":"2012","journal-title":"Urol Ann."},{"issue":"29","key":"10.1016\/j.jare.2025.06.009_b1645","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2217\/fon-2020-0434","article-title":"Future directions in advanced penile cancer - mechanisms of carcinogenesis and a search for targeted therapy","volume":"16","author":"Teh","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b1650","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3389\/fimmu.2018.01253","article-title":"The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma","volume":"9","author":"Ottenhof","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1655","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.eururo.2018.09.022","article-title":"The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer","volume":"75","author":"van Dijk","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1660","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAI.0000000000000575","article-title":"Microsatellite instability: a predictive biomarker for cancer immunotherapy","volume":"26","author":"Chang","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1665","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1245\/s10434-018-6658-4","article-title":"An update on immunotherapy for solid tumors: a review","volume":"25","author":"Pham","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1670","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CJI.0000000000000221","article-title":"Evidence for efficacy of treatment with the anti-PD-1 mab nivolumab in radiation and multichemorefractory advanced penile squamous cell carcinoma","volume":"41","author":"Trafalis","year":"2018","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1675","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","article-title":"Patient derived organoids to model rare prostate cancer phenotypes","volume":"9","author":"Puca","year":"2018","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.jare.2025.06.009_b1680","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"issue":"7757","key":"10.1016\/j.jare.2025.06.009_b1685","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic characterization of metastatic breast cancers","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jare.2025.06.009_b1690","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-13-0699","article-title":"Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation","volume":"20","author":"Yang","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1695","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134824","article-title":"Transcriptomic silencing as a potential mechanism of treatment resistance","volume":"5","author":"Adashek","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1700","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol Mol Biol Rev"},{"issue":"283","key":"10.1016\/j.jare.2025.06.009_b1705","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"7719","key":"10.1016\/j.jare.2025.06.009_b1710","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jare.2025.06.009_b1715","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919856494","article-title":"Molecular targeted therapy of BRAF-mutant colorectal cancer","volume":"11","author":"Ducreux","year":"2019","journal-title":"Ther Adv Med Oncol."},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b1720","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov"},{"issue":"7790","key":"10.1016\/j.jare.2025.06.009_b1725","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1730","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.annonc.2019.09.001","article-title":"Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors","volume":"31","author":"Pros","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1735","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"44","key":"10.1016\/j.jare.2025.06.009_b1740","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.jare.2025.06.009_b1745","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/EDBK_242209","article-title":"What it takes to improve a first-generation inhibitor to a second-or third-generation small molecule","volume":"39","author":"Rodon Ahnert","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1750","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.celrep.2018.10.049","article-title":"BRAF splice variant resistance to RAF inhibitor requires enhanced MEK association","volume":"25","author":"Vido","year":"2018","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.jare.2025.06.009_b1755","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1760","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"},{"issue":"24","key":"10.1016\/j.jare.2025.06.009_b1765","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.1158\/0008-5472.CAN-18-1867","article-title":"Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer","volume":"78","author":"Redaelli","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1770","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","article-title":"EGFR-TKIs resistance via EGFR-independent signaling pathways","volume":"17","author":"Liu","year":"2018","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1775","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1780","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET Exon 14-mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b1785","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1790","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-18-1640","article-title":"Activation of KRAS mediates resistance to targeted therapy in MET Exon 14-mutant non-small cell lung cancer","volume":"25","author":"Suzawa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1795","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","article-title":"Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance","volume":"26","author":"Pearson","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1800","first-page":"677","article-title":"Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer. Trends","volume":"5","author":"Zhu","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jare.2025.06.009_b1805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00141","article-title":"Identification of actionable fusions as an anti-EGFR resistance mechanism using a circulating tumor DNA assay","volume":"3","author":"Clifton","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b1810","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.annonc.2020.04.008","article-title":"Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients","volume":"31","author":"Ross","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1815","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b1820","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1825","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41588-019-0554-0","article-title":"ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer","volume":"52","author":"Xu","year":"2020","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b1830","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1835","first-page":"360","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature reviews","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Clin Oncol"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b1840","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1845","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"issue":"6472","key":"10.1016\/j.jare.2025.06.009_b1850","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.aav4474","article-title":"Adaptive mutability of colorectal cancers in response to targeted therapies","volume":"366","author":"Russo","year":"2019","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1855","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41419-020-2307-5","article-title":"Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b1860","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/annonc\/mdy003","article-title":"Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution","volume":"29","author":"Venkatesan","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1865","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1870","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"9807","key":"10.1016\/j.jare.2025.06.009_b1875","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jare.2025.06.009_b1880","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jare.2025.06.009_b1885","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1890","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jare.2025.06.009_b1895","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b1900","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jare.2025.06.009_b1905","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b1910","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b1915","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.06.009_b1920","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.746922","article-title":"Recent advances in medical therapy for urological cancers","volume":"12","author":"Yuasa","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b1925","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b1930","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2025.06.009_b1935","doi-asserted-by":"crossref","DOI":"10.1177\/1756287220980192","article-title":"Enfortumab Vedotin in urothelial cancer","volume":"12","author":"Alt","year":"2020","journal-title":"Ther Adv Urol"},{"issue":"13","key":"10.1016\/j.jare.2025.06.009_b1940","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b1945","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jare.2025.06.009_b1950","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jare.2025.06.009_b1955","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jare.2025.06.009_b1960","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b1965","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/iju5.12144","article-title":"Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high","volume":"3","author":"Fujiwara","year":"2020","journal-title":"IJU Case Rep"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b1970","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1002\/cam4.2375","article-title":"Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer","volume":"8","author":"Tucker","year":"2019","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.jare.2025.06.009_b1975","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1980","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.3390\/ijms22062832","article-title":"Biomarker-oriented therapy in bladder and renal cancer","volume":"22","author":"Scholtes","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.jare.2025.06.009_b1985","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b1990","article-title":"A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC)","author":"Harshman","year":"2018","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b1995","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b2000","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jare.2025.06.009_b2005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002312","article-title":"Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors","volume":"7","author":"Moore","year":"2011","journal-title":"PLoS Genet"},{"issue":"9637","key":"10.1016\/j.jare.2025.06.009_b2010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jare.2025.06.009_b2015","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.jare.2025.06.009_b2020","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b2025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2015.10.017","article-title":"Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy","volume":"69","author":"Powles","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jare.2025.06.009_b2030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.596359","article-title":"MicroRNA signature in renal cell carcinoma","volume":"10","author":"Ghafouri-Fard","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b2035","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1159\/000484395","article-title":"Mir-144-3p promotes cell proliferation, metastasis, sunitinib resistance in clear cell renal cell carcinoma by downregulating ARID1A","volume":"43","author":"Xiao","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b2040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13167-023-00327-3","article-title":"Multi-omics identification of an immunogenic cell death-related signature for clear cell renal cell carcinoma in the context of 3P medicine and based on a 101-combination machine learning computational framework","volume":"14","author":"Liu","year":"2023","journal-title":"EPMA J"},{"issue":"4","key":"10.1016\/j.jare.2025.06.009_b2045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s13167-020-00226-x","article-title":"Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope?","volume":"11","author":"Crigna","year":"2020","journal-title":"EPMA J"},{"issue":"22","key":"10.1016\/j.jare.2025.06.009_b2050","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b2055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4598","article-title":"A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010)","author":"Uzzo","year":"2017","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b2060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS712","article-title":"Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564","author":"Quinn","year":"2018","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b2065","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy283.136","article-title":"A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (PTS) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914)","volume":"29","author":"Bex","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b2070","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jare.2025.06.009_b2075","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jare.2025.06.009_b0620","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.jare.2025.06.009_b2080","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jare.2025.06.009_b2085","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jare.2025.06.009_b2090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10122","key":"10.1016\/j.jare.2025.06.009_b2095","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"10031","key":"10.1016\/j.jare.2025.06.009_b2100","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jare.2025.06.009_b2105","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jare.2025.06.009_b2110","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.06.009_b2115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jare.2025.06.009_b2120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4524","article-title":"Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)","author":"Vuky","year":"2018","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225003959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225003959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:38:45Z","timestamp":1786135125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225003959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":421,"alternative-id":["S2090123225003959"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.06.009","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}